3Billion, an artificial intelligence (AI) driven diagnostics firm specializing in rare genetic disorders, is set for a major leap forward as it expands globally and enters the U.S. insurance market. The company is bolstering its long-term growth strategy by not only enhancing its diagnostic services but also venturing into drug development.
A recent report from Sang Sang Investment & Securities suggests that 3Billion is poised to elevate its performance, driven by increasing overseas revenue and successful penetration of the U.S. market.
The company’s competitive edge lies in its AI-powered genetic interpretation technology. This foundation has enabled 3Billion to offer diagnostic services for rare genetic disorders, attracting global medical institutions as clients. The company’s revenue surged to 11.7 billion KRW (about 7.9 million USD) last year, more than doubling from the previous year, with analysts projecting continued robust growth.
The full service segment, 3Billion’s core business, is spearheading this growth. Already utilized in over 70 countries, this service is rapidly increasing its share of overseas revenue. The company has secured steady demand across diverse regions, maintaining high customer retention rates and establishing a stable revenue stream.
The U.S. market represents a critical inflection point for 3Billion. The company has established a local subsidiary and is currently developing its testing infrastructure and insurance claim systems.
Given that the U.S. is the largest player in the global genetic diagnostics market, many industry watchers believe that securing insurance coverage will significantly impact the company’s financial performance.
3Billion has already obtained the U.S. Medical Procedure Classification Code (CPT) and meets key requirements such as Clinical Laboratory Improvement Amendments (CLIA) certification and College of American Pathologists (CAP) accreditation.
Industry experts anticipate that 3Billion could start generating revenue in the U.S. as early as this year. There’s optimism that securing a substantial volume of tests will swiftly improve profitability.
The company is also expanding its domestic operations. Moving beyond patient-focused diagnostics, 3Billion is broadening its scope to include newborn and family testing, with long-term plans to enter the screening test market. This strategy aims not just to expand services but to grow the overall demand for testing.
The AI software business is emerging as another growth driver. GEBRA, the company’s proprietary genetic variant interpretation solution, is increasing its revenue contribution by expanding to more countries through a subscription model.
3Billion is also accelerating its drug development efforts using diagnostic data. The company is exploring potential technology transfers by expanding its pipeline based on a platform for identifying genetic Targets and developing candidate substances.
In essence, 3Billion is evolving into a ‘data-driven biotech company’ that bridges the gap between diagnosis and treatment.
An industry analyst noted that given 3Billion’s technological prowess and global expansion potential, its growth prospects warrant close attention. Particularly, if the company achieves tangible results in the U.S. market, it could trigger a significant reevaluation of its corporate value.